



IFW

Docket No. CEN-5017USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :Marian Nakada et al.
Serial No. :10/808699.
Filed :March 24, 2004
Title :USE OF EMMPRIN ANTAGONISTS FOR THE TREATMENT OF
DISEASES ASSOCIATED WITH EXCESSIVE ANGIOGENESIS
Art Unit :5898
Examiner : Haddad, Maher M

Honorable Commissioner of Patents
Washington, D.C. 20231

April 28, 2006

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the RESTRICTION REQUIREMENT mailed March 30, 2006, in the above referenced application.


Applicants hereby provisionally elect the subject matter of Group I, Claims 8-9 and 15-18, drawn to a method of treating an angiogenesis dependent disease wherein the disease is cancer. This election is made with traverse inasmuch as it is the applicant's position that the subject matter of groups I-V are all angiogenesis mediated disease and are thus inextricably linked such that they do not constitute independent and distinct inventions as required by the statute. The Examiner is therefore respectfully requested to examine these groups together in one application.

As to the election of species, applicants provisionally elect the species where the disease is angioma, as recited in claim 9.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: _____


Kenneth J. Dow
Reg. No. 32890

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(610) 651-7422
Dated: April 28, 2006